IJO International Journal of Oncology 1019-6439 1791-2423 D.A. Spandidos 10.3892/ijo.2023.5583 ijo-63-06-05583 Corrigendum [Corrigendum] Fully human VEGFR2 monoclonal antibody BC001 attenuates tumor angiogenesis and inhibits tumor growth XuanZi-Xue LiLin-Na ZhangQi XuCheng-Wang YangDe-Xuan YuanYe AnYing-Hong WangShan-Shan LiXiao-Wen YuanShou-Jun 12 2023 23 10 2023 63 6 135 Copyright: © Xuan et al. 2023 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Int J Oncol 45: 2411-2420, 2014; DOI: 10.3892/ijo.2014.2690

Subsequently to the publication of the above paper, an interested reader drew to the authors' attention that, for the scratch wound assay experiments shown in Fig. 1 on p. 2413, the panels showing the '0 h' experiments for the respective incubations with VEGF or BC001 were apparently identical.

The authors were able to re-examine their original data files, and realized that this figure had been inadverently assembled incorrectly. The revised version of Fig. 1, containing the correct data for the '0 h / BC001' panel, is shown below. Note that the revisions made to this figure do not affect the overall conclusions reported in the paper. The authors are grateful to the Editor of International Journal of Oncology for allowing them the opportunity to publish this Corrigendum, and apologize to the readership for any inconvenience caused.

BC001 inhibits endothelial cells migration. After incubation with BC001, the migrated cells were decreased, compared to that of VEGF(+) group, this result showed BC001 inhibited HUVEC migration. Scale bar, 400 μm.